Latest News and Press Releases
Want to stay updated on the latest news?
-
OMX-0407: clinical-stage, spectrum selective SIK kinase inhibitor with dual effect on tumor growth and immune evasionIOMX-0675: best-in-class antibody targeting immunosuppressive receptors LILRB1...
-
MARTINSRIED / MUNICH, Germany, April 07, 2022 (GLOBE NEWSWIRE) -- iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint...